Shionogi & Co ( (SGIOF) ) has realeased its Q2 earnings. Here is a breakdown of the information Shionogi & Co presented to its investors.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shionogi & Co., Ltd. is a pharmaceutical company based in Tokyo, primarily focused on the research, development, and distribution of prescription drugs, with a significant presence in both domestic and international markets.
In its latest earnings report for the second quarter of fiscal year 2024, Shionogi & Co. has seen a decline in several key financial metrics compared to the previous year. The company’s revenue for the six-month period ending September 30, 2024, stood at 213.97 billion yen, marking a 7.2% decrease from the same period last year.
The earnings report highlights a 22.7% drop in operating profit to 75.87 billion yen, attributed to increased research and development expenses and changes in product mix. Despite these challenges, Shionogi’s overseas sales and royalty income showed strong growth, with the U.S. and European markets contributing significantly to the sales of its antibiotic, Cefiderocol.
Looking ahead, Shionogi has revised its financial forecast upwards for the fiscal year ending March 31, 2025, citing steady sales growth overseas and expected contributions from new products in its portfolio. The company’s strategic focus remains on expanding its market share in the treatment of infectious and quality-of-life diseases.
